Marc Feldmann sold $4,700 of FRMM
director at 180 Life Sciences Corp.. 25,000 shares at an average of $0.19, traded Dec 15, 2023, filed Dec 18, 2023.
Score components
- +15RoleDirector
- 0Trade size$5k at market
- +5Share of holdings soldSold 18% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-23-096503, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2023 | SOpen-market sale Common Stock | -25,000 | $0.19 | $4,700 | 115,497 | Dec 18, 2023 |
Related signals
Other insiders at 180 Life Sciences Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | FRMMsell 180 Life Sciences Corp. | Konstantin Lomashuk owner | $1.5M 250,000 shares | -17% | |
| 12Weak | FRMMsell 180 Life Sciences Corp. | Konstantin Lomashuk owner | $16k 2,562 shares | -0% | |
| 12Weak | FRMMsell 180 Life Sciences Corp. | Konstantin Lomashuk owner | $21k 3,387 shares | -0% | |
| 17Weak | FRMMsell 180 Life Sciences Corp. | Konstantin Lomashuk owner | $30k 4,802 shares | -0% | |
| 53Moderate | FRMMsell 180 Life Sciences Corp. | Elray Resources, Inc. other | $9.3M 2,998,000 shares | -69% | |
| 53Moderate | FRMMbuy 180 Life Sciences Corp. | James N. Woody Chief Executive Officer | $4,700 25,000 shares | +60% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.